The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The challenges with monitoring patients with lymphoma for cardiotoxicity
Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discusses the challenges associated with monitoring patients with lymphoma for cardiotoxicity, specifically when treated with anthracycline-containing chemotherapy or BTK inhibitors. There is a need to improve the identification of patients at risk for cardiac events, and Dr Wang mentions a study using artificial intelligence (AI) to study prior electrocardiograms (EKGs) in the hopes of identifying prognostic indications. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
